Open Orphan

Company will use money from listing to meet costs for flu drug trials, develop assets

Company says reduction of capital will allow it to return value to its shareholders

hVivo will develop a new SARS-CoV-2 challenge virus based on new emerging variants

Company says HVO-001 could be included as part of potential demerger

Contract with US biotechnology company concerns a respiratory syncytial virus

Irish clinical trials group will deliberately infect healthy young volunteers with virus

Prophylactic spray could be used against Covid-19

Dublin-listed pharmaceutical services company says new deal will run for another year

Vaccine could be one of the first to provide long-term immunity from Covid-19

Open Orphan subsidiary to manage Phase 2 clinical trial for European pharma company

Guidelines will cover manufacture of agents for use in controlled infection studies

‘All we have at this point is a very promising press release. But the signs are very promising’

Contract guarantees annual revenue for Dublin listed company

Contract with UK government could be worth up to £10m

Company led by Cathal Friel recorded revenues of £7.1m for its first half

Officials warn Covid infections across country ‘a week or two’ behind Dublin

Open Orphan’s hVivo unit will conduct world’s first human challenge trials of several vaccine candidates

Paris subsidiary Venn Life Sciences to work with oncology study enrolling 750 subjects

More listed businesses likely to take chance to bolster balance sheets if markets remain bullish

Sectors include health and safety, pharma, crop protection and refrigeration

Dublin-listed pharmaceutical services company says contract is with top three pharma group

New contract with Japanese company Carna Bioscience follows close collaboration on drug development planning and pre-clinical activities

Dublin listed company will carry out phase one trial at Hvivo facility

The pharmaceutical company has three months to acquire CHIMagents

Dublin-listed pharmaceutical services company publishes annual results for 2019

Company is developing a vaccine to guard against diseases such as malaria and zika

Agreement covers market access of newly developed medicine into EU and US markets

London subsidiary Hvivo will carry out testing at its lab with 48-hour turnaround

Challenge study models could speed up the development of a vaccine by up to three years

Antibody tests can detect if a person has had coronavirus before and has since recovered

As many as 100 potential Covid-19 candidate vaccines are now under development by biotech and research teams around the world

Company will deliberately expose humans to a coronavirus in bid for Covid-19 vaccine

Dublin-listed pharma group announces contract with European biotech company

Drug consulting services platform to use proceeds to fund growth and synergies

Pharma services company to build on an existing relationship with German company

New targets set for inclusion of women on leadership teams and in private companies

Markets report: aviation shares slump while Tesco’s expansion plans boost performance

Deal values Hvivo at £12.96m, with its shareholders owning 44.7% of enlarged company

Company to use funds to help boost revenues as it looks to double size of its laboratory

Empiric Logic’s data analysis tool will improve understanding of human health